NCT07149818View on ClinicalTrials.gov

A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia

Not yet recruitingOBSERVATIONAL

Enrollment

22

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions

Autoimmune Hemolytic Anemia

Interventions

DRUG

Parsaclisib

parsaclisib 40mg qd

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER